These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 20127392)
1. HIV therapeutic possibilities of gold compounds. Fonteh PN; Keter FK; Meyer D Biometals; 2010 Apr; 23(2):185-96. PubMed ID: 20127392 [TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
3. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420 [TBL] [Abstract][Full Text] [Related]
4. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy. Chiappini E; Galli L; Zazzi M; de Martino M J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711 [TBL] [Abstract][Full Text] [Related]
5. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes. Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628 [TBL] [Abstract][Full Text] [Related]
6. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression. Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396 [TBL] [Abstract][Full Text] [Related]
8. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
9. Long-Term suppression of HIV infection: benefits and limitations of current treatment options. Sension MG J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719 [TBL] [Abstract][Full Text] [Related]
10. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections]. Pozio E Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694 [TBL] [Abstract][Full Text] [Related]
12. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F; Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377 [TBL] [Abstract][Full Text] [Related]
13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741 [TBL] [Abstract][Full Text] [Related]
14. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V; J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728 [TBL] [Abstract][Full Text] [Related]
15. Therapy of HIV infection. Chang YC; Tyring SK Dermatol Ther; 2004; 17(6):449-64. PubMed ID: 15571495 [TBL] [Abstract][Full Text] [Related]
16. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients? Cuzin L; Allavena C; Morlat P; Dellamonica P AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976 [TBL] [Abstract][Full Text] [Related]
17. Molecular biological assessment methods and understanding the course of the HIV infection. Katzenstein TL APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050 [TBL] [Abstract][Full Text] [Related]
18. New drugs for old. Winston A; Stebbing J J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729 [TBL] [Abstract][Full Text] [Related]
19. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy. Kulkosky J; Pomerantz RJ Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572 [TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]